Chronic stable angina guidelines: Is there an emerging international consensus?

British Journal of Cardiology

Volumn 19, Issue SUPPL.2, 2012, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; NICORANDIL; RANOLAZINE;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; COMORBIDITY; CONSENSUS; CORONARY ARTERY RECANALIZATION; CORONARY RISK; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXERCISE TEST; HEALTH CARE SYSTEM; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LONGEVITY; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY PREVENTION; SMOKING CESSATION; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; T WAVE INVERSION; THORAX PAIN;

EID: 84876516232     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: 10.5837/bjc.2012.s06     Document Type: Article

References (51)

1. Hemingway H, Langenberg C, Damant J, Frost C, Pyörälä K, Barrett-Connor E. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation 2008;117:1526-36. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.720953 (Pubitemid 351440641)
2. World Health Organization. The Atlas of Heart Disease and Stroke. The future of CVD. Available at: http://www.who.int/cardiovascular-diseases/en/cvd- atlas-25-future.pdf. [Accessed 29 February 2012].
3. Daly CA, Clemens F, Sendon JL, et al. The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the frst month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26:1011-22. http://dx.doi.org/10.1093/eurheartj/ehi109 (Pubitemid 40695032)
4. Daly CA, De Stavola B, Sendon JL, et al. Predicting prognosis in stable angina - results from the Euro Heart Survey of stable angina: prospective observational study. BMJ 2006;332:262-7. http://dx.doi.org/10.1136/bmj.38695. 605440.AE
5. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010;362:886-95. http://dx.doi.org/10.1056/ NEJMoa0907272
6. Sekhri N, Feder GS, Junghans C, Hemingway H, Timmis AD. How effective are rapid access chest pain clinics? Prognosis of incident angina and non-cardiac chest pain in 8762 consecutive patients. Heart 2007; 93:458-63. http://dx.doi.org/10.1136/hrt.2006.090894 (Pubitemid 46631511)
7. Buckley B, Murphy AW. Do patients with angina alone have a more benign prognosis than patients with a history of acute myocardial infarction, revascularisation or both? Findings from a community cohort study. Heart 2009;95:461-7. http://dx.doi.org/10.1136/hr t.2008.146944
8. Hemingway H, Vahtera J, Virtanen M, Pentti J, Kivimäki M. Outcome of stable angina in a working population: the burden of sickness absence. Eur J Cardiovasc Prev Rehabil 2007;14:373-9. http://dx.doi.org/10.1097/01.hjr. 0000230106.01396.a2 (Pubitemid 46945559)
9. Boden WE, O'Rourke RA, Teo KK, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-16. http://dx.doi.org/10.1056/NEJMoa070829 (Pubitemid 46588415)
10. Shaw LJ, Berman DS, Maron DJ et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.743963 (Pubitemid 351365675)
11. Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic beneft derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011; 32:1012-24. http://dx.doi.org/10.1093/eurheartj/ehq500
12. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival beneft associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900-07. http://dx.doi.org/10.1161/01. CIR.0000072790. 23090.41
13. Pfsterer ME, Zellweger MJ, Gersh BJ. Management of stable coronary artery disease. Lancet 2010;375:763 - 72. http://dx.doi.org/10.1016/S0140-6736(10) 60168-7
14. Tonino PAL, De Bruyne B, Pijls NH, et al. Fractional fow reserve versus angiography for guiding percutaneous coronary angiography. N Engl J Med 2009;360:213-24. http://dx.doi.org/10.1056/NEJMoa0807611
15. Hachamovitch R, Nutter B, Hlatky MA, et al. Patient management after noninvasive cardiac Imaging results from SPARC (Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in Coronary Artery Disease). J Am Coll Cardiol 2012;59:462-74. http://dx.doi.org/10.1016/j.jacc.2011.09.066
16. Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 2011; 305:1882-9. http://dx.doi.org/10.1001/jama. 2011.601
17. Fox K, Alonso Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: full text. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006. http://dx.doi.org/10.1093/eurheartj/ehl002
18. Fraker TD Jr, Fihn SD; 2002 Chronic Stable Angina Writing Committee; American College of Cardiology; American Heart Association, Gibbons RJ et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007; 50:2264-74. http://dx.doi.org/10.1016/j.jacc.2007.08.002 (Pubitemid 350166813)
19. National Institute for Health and Clinical Excellence. NICE clinical guideline 126. Management of stable angina. July 2011. Available at http://www.nice.org.uk/CG126 [accessed 10 February 2012].
20. National Institute for Health and Clinical Excellence. NICE clinical guideline 95. Chest pain of recent onset: Assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. March 2010. Available at: http://guidance. nice.org.uk/CG95 [accessed 15 February 2012].
21. Einstein AJ, Weiner SD, Bernheim A, et al. Multiple testing, cumulative radiation dose, and clinical indications in patients undergoing myocardial perfusion imaging. JAMA 2010;304:2137-44. http://dx.doi.org/10.1001/jama.2010. 1664
22. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16. http://dx.doi.org/10.1001/jama.290.21.2805 (Pubitemid 37509488)
23. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology and management. Circulation 2010;121:2317-25. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.900191
24. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830-40. http://dx.doi.org/10.1056/NEJMra061889
25. Poole-Wilson PA, Lubsen J, Kirwan BA et al; Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364: 849-57. http://dx.doi.org/10.1016/ S0140-6736(04)16980-8
26. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing ß-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281:1927-36. http://dx.doi.org/10.1001/jama.281.20.1927 (Pubitemid 29242807)
27. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Effcacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-36. http://dx.doi.org/10.1093/eurheartj/ehi586 (Pubitemid 41677303)
28. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; on behalf of the Beautiful Investigators. Ivabradine for patients with stable coronary artery disease and left ventricular dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008;372:807-16. http://dx.doi.org/10.1016/ S0140-6736(08)61170-8
29. Reil JC, Bohm M. BEAUTIIFUL results-the slower, the better? Lancet 2008;372:779-80. http://dx.doi.org/10.1016/S0140-6736(08)611172-1
30. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85. http://dx.doi.org/10.1016/S0140-6736(10)61198-1
31. NeLM news service. European CHMP supports license extension for ivabradine (Procoralan® ). 28 September 2009. Available at: http://www.nelm.nhs.uk/en/NeLM-Area/News/2009-September/28/European-CHMP- supports-license-extension-for-ivabradine-Procorala n/?query= IVABRADINE&rank=44. [Accessed 29 February 2012].
32. NeLM news service. European CHMP recommends approval of license extension for ivabradine (Procoralan) as treatment of chronic heart failure (NYHA II to IV) and updates contra-indications. 16 December 2011. Available at: http://www.nelm.nhs.uk/en/NeLM-Area/News/2011-December/16/European-CHMP- recommends-approval-of-license-extension-for-ivabradine-Procoralan-as-treatment- of-chronic-heart-failure-NYHA-II-to-IV-and-updates-contra-indications/?quer y=IVABRADINE&rank=35. [Accessed 29 February 2012].
33. Chaitman BR, Skettino SL, Parker JO, et al; MARISA Investigators. Anti-ischemic effects and longterm survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82. http://dx.doi.org/10.1016/j.jacc.2003.11.045 (Pubitemid 38496341)
34. Chaitman BR, Pepine CJ, Parker JO, et al; for the CARISA Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-16. http://dx.doi.org/10.1001/ jama.291.3.309 (Pubitemid 38101603)
35. NeLM news service. European CHMP adopts positive opinion on ranolazine (Latixa) for the treatment of stable angina pectoris. 25 April 2008. Available at: http://www.nelm.nhs.uk/en/NeLM-Area/News/494080/494359/494371/?query= RANOLAZINE&rank=33. [Accessed 29 February 2012].
36. Conti CR. Ranolazine and silent ischemia. J Am Coll Cardiol 2011; 58:1083. [letter] http://dx.doi.org/10.1016/j.jacc.2010.11.084
37. Pelliccia F, Marazzi G, Pasceri V, et al. Usefulness of preprocedural therapy with ranolazine to prevent myocardial damage in percutaneous coronary intervention. Abstract: P2355, European Society of Cardiology Congress, Aug/Sept 2011. Available at: http://spo. escardio.org/AbstractDetails. aspx?id=98382&eevtid=48. [Accessed 29 February 2012].
38. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Effciency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.724880 (Pubitemid 47537839)
39. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032-9. doi:10.1161/CIRCULATIONAHA.107.763912.
40. Timmis AD, Bernard R, Chaitman BR, et al. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27:42-8. http://dx.doi.org/10.1093/eurheartj/ehi495 (Pubitemid 41785931)
41. Morrow DA, Scirica BM, Sabatine MS, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes. Observations from the MERLIN-TIMI 36 trial. J Am Coll Cardiol, 2010;55:1189-96. http://dx.doi.org/10.1016/j. jacc.2009.09.068
42. Jacobshagen C, Belardinelli L, Hasenfuss G, Maier LS. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol. 2011; 34:426-32. http://dx.doi.org/10.1002/clc.20897
43. Maier L, Wachter R, Edelmann F, et al. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: results from the RALI-DHF study. J Am Coll Cardiol 2012;59:865. doi:10.1016/S0735- 1097(12)60866-3.
44. Tsuchida A, Miura T, Tanno M et al. Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemmal K(ATP) channels, and protein kinase C. J Am Coll Cardiol 2002;40:1523-30. http://dx.doi.org/10. 1016/S0735-1097(02)02268-4 (Pubitemid 35192880)
45. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-75. http://dx.doi.org/10.1016/S0140-6736(02)08265-X
46. Sakata Y, Nakatani D, Shimizu M, et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol 2012;59:14-21. http://dx.doi.org/10.1016/j. jjcc.2011.08.001
47. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomized trials. Lancet 2007; 370:1483-93. http://dx.doi.org/ 10.1016/S0140-6736(07)61634-1 (Pubitemid 47625560)
48. Steg PG. Baseline data of the CLARIFY registry. Presented at the European Society of Cardiology Congress, Paris, August-September, 2011.
49. Macchia A, Romero M, D'Ettorre A, Mariani J, Tognoni G. Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. Eur Heart J 2012;33:515-22. http://dx.doi.org/10.1093/eurheartj/ehr410
50. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 1999;138:577-85. http://dx.doi.org/10.1016/S0002- 8703(99)70163-8 (Pubitemid 29428783)
51. Elder DH, Pauriah M, Lang CC, et al. Is there a Failure to Optimize theRapy in anGina pEcToris (FORGET) study? QJM 2010;103:305-10. http://dx.doi.org/10.1093/qjmed/hcq011